Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45 th Annual Health Care Conference on March 4, ...

Pfizer has agreed to pay $59,746,277.54 ... and honoraria payments to health care providers to encourage them to prescribe Nurtec ODT (Nurtec), a prescription medication for migraine treatment.

Pfizer's Q4 adjusted EPS was $0.63 ... This was primarily driven by legacy Seagen, Vyndaqel family, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by lower revenues for Abrysvo, Xeljanz ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer recently announced better-than-expected Q4 results. Products picked up with the acquisition of Seagen were big contributors to growth, including Adcetris and Padcev. So were other acquired ...

Nurtec ODT/Vydura sales jumped 39% to $392 million ... and Abrysvo RSV vaccine sales slumped 62% to $198 million. Guidance: Pfizer reaffirms 2025 revenues of $61 billion-$64 billion compared ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

Pfizer expects to sufficiently de-lever its ... and generic competition in certain international markets; Nurtec ODT/Vydura globally, up 39% operationally, driven primarily by strong demand ...